Platelet aggregation pathway protein

"Platelet aggregation pathway proteins" is not a single molecular target but rather an umbrella term encompassing a diverse set of **proteins involved in the process of platelet activation and aggregation**. These include several key **receptors** on the platelet surface—such as **P2Y12**, **P2Y1**, **PAR1**, and **PAR4** (all G-protein–coupled receptors), as well as integrins like **glycoprotein IIb/IIIa (GPIIb/IIIa)**—and their associated intracellular signaling molecules[1][5][6]. Upon vascular injury or exposure to agonists like ADP, thrombin, or collagen, these receptors mediate signal transduction events that result in conformational changes in platelets and promote their clumping to form a hemostatic plug[5]. Therapeutic agents such as clopidogrel, prasugrel, ticagrelor (targeting P2Y12), and aspirin (targeting thromboxane A2 synthesis) are designed to inhibit specific steps within this complex network to prevent pathological thrombosis but can increase bleeding risk[1][3]. The term "platelet aggregation pathway proteins" is therefore too broad for use as a canonical drug target; it refers collectively to many distinct molecular entities rather than one specific protein or receptor. Because this entry does not refer to a unique molecule but instead describes an entire biological process involving numerous targets from different molecular families—including GPCRs, integrins, enzymes—it should be flagged as incorrect for structured drug-target databases. For precise information retrieval or therapeutic targeting purposes, individual components such as "P2Y12 receptor," "Glycoprotein IIb/IIIa," or "Protease activated receptor 1" should be specified instead[6].

Other names

Platelet aggregation proteinsPlatelet activation pathway proteinsPlatelet signaling proteins

Inhibition of ADP-mediated platelet activation via P2Y12 receptor antagonism[1][3] - Inhibition of thromboxane A2 synthesis (Aspirin)[8]